Research programme: CNS disorders therapeutics - Chronos Therapeutics

Drug Profile

Research programme: CNS disorders therapeutics - Chronos Therapeutics

Latest Information Update: 25 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shire
  • Developer Chronos Therapeutics
  • Class
  • Mechanism of Action Central nervous system modulators; Orexin receptor type 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fatigue; Impulse control disorders; Post-traumatic stress disorders

Most Recent Events

  • 25 Jul 2016 Chronos Therapeutics acquires CNS disorders therapeutics from Shire
  • 20 Jul 2016 Preclinical trials in Post-traumatic stress disorder, Impulse control disorders, and Fatigue in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top